Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004

BJU International

Volumn 101, Issue 5, 2008, Pages 547-555

  Hussain, Sabina ^a   Gunnell, David ^a   Donovan, Jenny ^a   McPhail, Sean ^b   Hamdy, Freddie ^c   Neal, David ^d   Albertsen, Peter ^e   Verne, Julia ^b   Stephens, Peter ^f   Trotter, Caroline ^a   Martin, Richard M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b South West Public Health Observatory   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f IQVIA   (United States)

Author keywords

Antiandrogens; LHRH analogues; Mortality; Prostate cancer; PSA screening; Radical prostatectomy; Secular trends

Indexed keywords

ANTIANDROGEN; ESTROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CONFIDENCE INTERVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UNITED KINGDOM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ENGLAND; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; WALES;

EID: 38849168891     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07338.x     Document Type: Article

References (71)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001 37 (Suppl. 8 4 66
2. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000 85 : 60 7
3. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the 'PSA ERA Int J Cancer 2001 92 : 893 8
4. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001 58 : 417 24
5. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973-94: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998 52 : 444 8
6. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998 82 : 249 51
7. Donovan JL, Martin RM, Neal DE, Hamdy FC. Prostate cancer: screening approaches. Br J Hospital Med 2005 66 : 623 6
8. Martin RM, Davey Smith G, Donovan J. Does current evidence justify prostate cancer screening in Europe? Nature Clin Prac Oncol 2005 2 : 538 9
9. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003 361 : 1122 8
10. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006 94 : 1361 8
11. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer. estimating the magnitude of overdetection. CMAJ 1998 159 : 1368 72
12. Draisma G, Boer R, Otto SJ et al. Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 95 : 868 78
13. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer Part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999 91 : 1033 9
14. Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003 168 : 31 5
15. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 1998 90 : 1230 1
16. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. The Lancet 2000 355 : 1788 9
17. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002 325 : 740 3
18. Shaw PA, Etzioni R, Zeliadt SB et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 2004 160 : 1059 69
19. Donovan J, Martin R. Screening for prostate cancer. Int J Epidemiol 2007 36 : 30
20. Andriole GL, Levin DL, Crawford ED et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005 97 : 433 8
21. De Koning HJ, Auvinen A, Berenguer SA et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002 97 : 237 44
22. ONS. Cancer statistics - registrations, England 2003. Series MB1. No. 34. London : Office for National Statistics, 2005
23. Brock A, Griffiths C, Rooney C. The effect of the introduction of ICD-10 on cancer mortality trends in England and Wales. Health Statistics Q 2004 23 : 7 17
24. Anonymous. Results of the ICD-10 bridge coding study, England and Wales, 1999. Health Statistics Q 2002 14 : 75 83
25. ONS. Annex I Series DH2. No. 28 Mortality Statistics Cause. Review of the Registrar General on Deaths by Cause, Sex and Age, in England and Wales 2001. Office of National Statistics, 2002
26. Rooney C, Griffiths C, Cook L. The implementation of ICD-10 for cause of death coding - some preliminary results from the bridge coding study. Health Statistics Q 2002 13 : 31 41
27. Rooney C, Devis T. Mortality trends by cause of death in England and Wales 1980-94: the impact of introducing automated cause coding and related changes in 1993. Population Trends 1996 86 : 29 35
28. IMS UK. Available at http://research.imshealth.com/contactus.htm Accessed October 2007
29. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statistics Med 2000 19 : 335 51
30. Lerman PM. Fitting segmented regression models by grid search. Appl Stat 1980 29 : 77 84
31. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997 79 (Suppl. 3 1 32
32. Melia J, Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001 85 : 656 7
33. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004 94 : 51 6
34. Oliver SE, Donovan JL, Peters TJ, Frankel S, Hamdy FC, Neal DE. Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. BJU Int 2003 91 : 331 6
35. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. New England J Med 2005 352 : 1977 84
36. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA J Am Med Assoc 2005 17 : 2005
37. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005 23 : 441 7
38. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer Part II. Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999 91 : 1025 32
39. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenex M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what has happened in the last 20 years. J Urol 2004 172 : 1297 301
40. Demers RY, Tiwari A, Wei J, Weiss LK, Severson RK, Montie J. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer 2001 92 : 2309 17
41. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003 95 : 981 9
42. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005 103 : 1615 24
43. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 321 : 419 24
44. Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol 1992 147 : t 5
45. Pilepich MV, John MJ, Krall JM, McGowan D, Hwang YS, Perez CA. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Am J Clin Oncol 1990 13 : 461 4
46. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 : 1781 8
47. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997 337 : 295 300
48. Caubet JF, Tosteson TD, Dong EW et al. Maximum androgen blockade in advanced prostate cancer. A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997 49 : 71 8
49. Klotz L. Combined androgen blockade in prostate cancer. meta-analyses and associated issues. BJU Int 2001 87 : 806 13
50. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer. an overview of the randomised trials. Lancet 2000 355 : 1491 8
51. Damber JE. Decreasing mortality rates for prostate cancer. possible role of hormonal therapy? BJU Int 2004 93 : 695 701
52. Sydes MR, Stephens RJ, Moore AR et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397). methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy Oncol 2004 72 : 199 211
53. Potosky AL, Kessier L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 1990 82 : 1624 8
54. Judge A, Evans S, Gunnell D, Albertsen P, Verne J, Martin RM. Patient outcomes and length of hospital stay after radical prostatectomy for prostate cancer: analysis of Hospital Episodes Statistics for England. BJU Int 2007 Sep 3 Epub ahead of print
55. D'Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007 25 : 2420 5
56. Hoffman RM, Stone SN, Hunt WC, Key CR, Gilliland FD. Effects of misattribution in assigning cause of death on prostate cancer mortality rates. Ann Epidemiol 2003 13 : 450 4
57. Miller AB, Yurgalevitch S, Weissfeld L. Death review process in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Controlled Clin Trials 2000 21 (6 Suppl. 1 400S 6S
58. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? JNCI 2001 93 : 1822 3
59. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000 92 : 613 21
60. Post PN, Straatman H, Kiemeney LA, Coebergh JW. Increased risk of fatal prostate cancer may explain the rise in mortality in The Netherlands. Int J Epidemiol 1999 28 : 403 8
61. Takahashi E. Growth and environmental factors in Japan. Human Biol 1966 38 : 112 30
62. Rogers I, Metcalfe C, Gunnell D et al. Insulin-like growth factor-I and growth in height, leg length, and trunk length between ages 5 and 10 years. J Clin Endocrinol Metab 2006 91 : 2514 9
63. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1999: Estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2004 34 : 352 6
64. Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 2000 85 : 463 73
65. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening. Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 94 : 981 90
66. Evans HS, Moller H. Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol 2003 43 : 337 41
67. Severson RK. Have transurethral resections contributed to the increasing incidence of prostatic cancer? J Natl Cancer Inst 1990 82 : 1597 9
68. Eisenberger M, Partin A. Progress toward identifying aggressive prostate cancer. N Engl J Med 2004 351 : 180 1
69. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 2002 94 : 958 60
70. Litwin MS, Hays RD, Fink A et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995 273 : 129 35
71. Donovan J, Mills N, Smith M et al. Quality improvement report. Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002 325 : 766 70